The study used a benchtop implementation of the wireless implantable neural interface Brain Interchange (BIC) alongside a clinical-grade amplifier. Despite BIC’s lower sampling rate, narrower analog bandwidth, and higher noise floor, the integrated sparse signal processing and machine learning artifact removal maintained nearly identical spatial distribution of pathological activity. The authors, affiliated with Mayo Clinic and other institutions, noted that the framework supports chronic tracking of evolving epileptogenic networks and future biomarker-guided adaptive neuromodulation.
Implant-Grade BCI Preserves Epilepsy HFO Biomarkers, Maps Onset Zone at 84% Sensitivity
Summary
A wireless implantable neural interface, the Brain Interchange (BIC), paired with artifact-removal algorithms captured about 82% of the high-frequency oscillations (HFOs) that a clinical-grade amplifier detected across 24-hour intracranial EEG recordings in 10 patients with drug-resistant epilepsy, according to a preprint. Using those HFOs, the system localized the seizure onset zone with 84% sensitivity and 90% specificity, comparable to clinical equipment. The authors present the work as a translational framework for chronic tracking of epileptogenic networks and for future biomarker-guided adaptive neuromodulation.
Why it matters
HFO biomarkers were defined on rack-mounted clinical amplifiers, so the open question for closed-loop neuromodulation was whether they survive the move onto an implant's narrower, noisier sensing chain. Preserving 82% of individual events while still localizing the onset zone at 84% sensitivity suggests the clinically useful signal is spatial rather than event-by-event, which is a much easier specification for a chronic device to meet. The evidence is 10 patients over 24 hours, in a preprint.
Compiled by BCIwiki from public sources
Sources · 1
pubmed.ncbi.nlm.nih.gov 2026-09-03